Group One Trading’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-9,357
| Closed | -$4.15M | – | 8603 |
|
|
2026
Q1 | $4.18M | Buy |
+9,357
| New | +$4.36M | 0.01% | 1444 |
|
|
2025
Q4 | – | Sell |
-8,889
| Closed | -$3.83M | – | 9260 |
|
|
2025
Q3 | $3.48M | Buy |
8,889
+3,037
| +52% | +$1.27M | 0.01% | 1814 |
|
|
2025
Q2 | $2.61M | Buy |
+5,852
| New | +$2.7M | 0.01% | 1881 |
|
|
2025
Q1 | – | Sell |
-30,402
| Closed | -$14.2M | – | 8439 |
|
|
2024
Q4 | $12.2M | Buy |
30,402
+6,079
| +25% | +$2.82M | 0.03% | 593 |
|
|
2024
Q3 | $11.3M | Buy |
24,323
+14,886
| +158% | +$7.15M | 0.03% | 551 |
|
|
2024
Q2 | $4.42M | Sell |
9,437
-5,696
| -38% | -$2.47M | 0.02% | 881 |
|
|
2024
Q1 | $6.33M | Buy |
+15,133
| New | +$6.4M | 0.02% | 683 |
|
|
2023
Q1 | – | Sell |
-45,103
| Closed | -$13.5M | – | 8030 |
|
|
2022
Q4 | $13M | Buy |
45,103
+20,221
| +81% | +$6.16M | 0.03% | 591 |
|
|
2022
Q3 | $7.2M | Buy |
24,882
+4,222
| +20% | +$1.21M | 0.01% | 920 |
|
|
2022
Q2 | $5.82M | Buy |
20,660
+5,344
| +35% | +$1.43M | 0.01% | 1182 |
|
|
2022
Q1 | $4M | Sell |
15,316
-83,121
| -84% | -$19.7M | ﹤0.01% | 1731 |
|
|
2021
Q4 | $21.6M | Buy |
98,437
+26,514
| +37% | +$5.16M | 0.02% | 648 |
|
|
2021
Q3 | $13M | Buy |
71,923
+5,362
| +8% | +$1.05M | 0.01% | 877 |
|
|
2021
Q2 | $13.4M | Sell |
66,561
-16,319
| -20% | -$3.41M | 0.02% | 873 |
|
|
2021
Q1 | $17.8M | Sell |
82,880
-16,367
| -16% | -$3.59M | 0.03% | 603 |
|
|
2020
Q4 | $23.5M | Buy |
+99,247
| New | +$22.8M | 0.04% | 379 |
|
|
2020
Q2 | – | Sell |
-11,669
| Closed | -$3.16M | – | 6225 |
|
|
2020
Q1 | $2.78M | Buy |
+11,669
| New | +$2.68M | 0.02% | 840 |
|
|
2018
Q2 | – | Sell |
-6,533
| Closed | -$1.01M | – | 5519 |
|
|
2018
Q1 | $1.06M | Sell |
6,533
-16,837
| -72% | -$2.75M | 0.01% | 1480 |
|
|
2017
Q4 | $3.5M | Buy |
+23,370
| New | +$3.46M | 0.02% | 841 |
|
|
2017
Q3 | – | Sell |
-17,571
| Closed | -$2.64M | – | 5199 |
|
|
2017
Q2 | $2.26M | Buy |
+17,571
| New | +$2.12M | 0.02% | 884 |
|
|
2017
Q1 | – | Sell |
-11,888
| Closed | -$1.05M | – | 5037 |
|
|
2016
Q4 | $876K | Buy |
11,888
+3,724
| +46% | +$303K | 0.01% | 1401 |
|
|
2016
Q3 | $712K | Sell |
8,164
-859
| -10% | -$81.2K | 0.01% | 1538 |
|
|
2016
Q2 | $776K | Buy |
9,023
+4,202
| +87% | +$363K | 0.01% | 1411 |
|
|
2016
Q1 | $383K | Buy |
+4,821
| New | +$436K | 0.01% | 1871 |
|
|
2015
Q4 | – | Sell |
-2,362
| Closed | -$285K | – | 5136 |
|
|
2015
Q3 | $246K | Sell |
2,362
-1,500
| -39% | -$193K | ﹤0.01% | 2355 |
|
|
2015
Q2 | $477K | Buy |
+3,862
| New | +$487K | 0.01% | 1820 |
|
|
2015
Q1 | – | Sell |
-30,402
| Closed | -$3.64M | – | 5240 |
|
|
2014
Q4 | $3.61M | Sell |
30,402
-31,750
| -51% | -$3.58M | 0.05% | 396 |
|
|
2014
Q3 | $6.98M | Buy |
+62,152
| New | +$5.92M | 0.11% | 197 |
|
|
2014
Q2 | – | Sell |
-9,164
| Closed | -$643K | – | 5524 |
|
|
2014
Q1 | $648K | Sell |
9,164
-22,628
| -71% | -$1.79M | 0.01% | 1440 |
|
|
2013
Q4 | $2.36M | Sell |
31,792
-27,434
| -46% | -$1.91M | 0.04% | 562 |
|
|
2013
Q3 | $4.49M | Buy |
59,226
+52,390
| +766% | +$4.17M | 0.09% | 239 |
|
|
2013
Q2 | $546K | Buy |
+6,836
| New | +$503K | 0.01% | 1270 |
|
Other funds holding VRTX
Group One Trading's VRTX Position: Q2 2026 in Review
Group One Trading sold out of Vertex Pharmaceuticals (VRTX) in Q2 2026, closing a stake of 9,357 shares — an estimated $4.15M sold.
Group One Trading first reported a position in VRTX in Q2 2013 and held it in 32 quarters. The position peaked at $23.5M in Q4 2020. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.
- Group One Trading reported no remaining Vertex Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Group One Trading sold 9,357 Vertex Pharmaceuticals shares in Q2 2026, an estimated $4.15M.
- Group One Trading first reported a position in Vertex Pharmaceuticals in Q2 2013 and held it in 32 quarters.
- Group One Trading's Vertex Pharmaceuticals position peaked at $23.5M in Q4 2020.
- 1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.
Based on Group One Trading's 13F filing for Q2 2026, filed 14 Aug 2026.